Skip to main content
SpringerLink
Log in

Pharmacogenomic-Guided Drug Development

  • Reference work entry
Drug Discovery and Evaluation: Methods in Clinical Pharmacology

  • 2154 Accesses

Abstract

In an ideal world, a pharmaceutical drug would be highly effective without side effects in patients correctly predicted to be susceptible to the beneficial effects of the respective drug. The drug manufacturer would be able to identify a disease entity worth investing in, because reimbursement would be assured. On the basis of genomic knowledge, molecular diseases and treatment targets would be readily identifiable, and their validation would pose no problem in terms of investment and time due to the availability of appropriate technology. Biomarkers (already validated) should guide an accelerated clinical development process to regulatory approval ensuring no unpleasant surprises concerning safety in the post-approval period.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 549.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

REFERENCES AND FURTHER READING

  • Armstrong M, Bromley C, Cohen N, Hunt CM, O’Neill R, Power A (2009) Commentary from the 3rd FDA–DIA–PWGPhRMA–BIO pharmacogenomics workshop. Pharmacogenomics 10:117–125

    Article  PubMed  Google Scholar 

  • Besany D, Zhang Z (2004) Bioinformatics and cancer target discovery. Drug Discov Today 9:795–802

    Article  Google Scholar 

  • Bromley CM, Close S, Cohen N, Favis R, Fijal B, Gheyas B, Liu W, Lopez-Correa C, Prokop A, Singer JB, Snapir A, Tchelet A, Wang D, Goldstaub D (2009) Designing pharmacogenetic projects in industry: practical design perspectives from the industry pharmacogenomics working group. Pharmacogenomics J 9:14–22

    Article  CAS  PubMed  Google Scholar 

  • Chen X, Jorgenson E, Cheung ST (2009) New tools for functional genomic analysis. Drug Discov Today 14:754–760

    Article  CAS  PubMed  Google Scholar 

  • Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, Ma P (2009) The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov 8:279–286

    Article  CAS  PubMed  Google Scholar 

  • EFPIA (2009) 2nd EMEA–EFPIA workshop on adaptive design in confirmatory clinical trials. http://www.efpia.org/Content/Default.asp?PageID=607

  • EMEA (2007) Reflection paper on the methodological issues in confirmatory clinical trials planned with an adaptive design. http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf

  • EMEA (2008) Report on the EMEA-EFPIA workshop on adaptive designs in confirmatory clinical trials. http://www.emea.europa.eu/pdfs/conferenceflyers/report_adaptivedesigns.pdf

  • EMEA/EFPIA (2009) Pharmacogenetics workshop on integrating pharmacogenetics early into drug development: PK as a working exam-ple. http://www.emea.europa.eu/pdfs/human/pharmacogenetics/15162309en.pdf

  • European Parliament and Council (1998) Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Official Journal L 331, 07/12/1998: 1-37, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1998:331:0001:0037:EN:PDF

  • Fan C et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569

    Article  CAS  PubMed  Google Scholar 

  • Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT (2009) Clinically available pharmacogenomics tests. Clin Pharm Ther 86:109–113

    Article  CAS  Google Scholar 

  • Frueh FW, Salerno RA, Lesko LJ, Hockett RD (2009) 4th FDA US FDA–drug information association pharmacogenomics workshop, held 10–12 December 2007. Pharmcogenomics 10:111–115

    Article  Google Scholar 

  • Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:998–1009

    Article  CAS  PubMed  Google Scholar 

  • Grossman I (2009) ADME pharmacogenetics: current practices and future outlook. Expert Opin Drug Metab Toxicol 5:449–462

    Article  CAS  PubMed  Google Scholar 

  • Gupta M, Kaur H, Grover S, Kukreti R (2008) Pharmacogenomics and treatment for dementia induced by Alzheimer’s disease. Pharmacogenomics 9:895–903

    Article  CAS  PubMed  Google Scholar 

  • Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters SP, Weiss ST, Bleecker ER (2006) Sequence, haplotype and association analysis of ADRβ2 in multi-ethnic asthma case–control subjects. Am J Respir Crit Care Med 174:1101–1109

    Article  CAS  PubMed  Google Scholar 

  • Hinman LM, Huang SM, Hackett J, Koch WH, Love PY, Pennello G, Torres-Cabassa A, Webster C (2006) The drug diagnostic co-development concept paper. Commentary from the 3rd FDA–DIA–PWGPhRMA–BIO pharmacogenomics workshop. Pharmacogenomics J 6:375–380

    Article  CAS  PubMed  Google Scholar 

  • Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13

    Article  CAS  PubMed  Google Scholar 

  • International Cancer Genome Project (contin. updated). ICGC http://www.icgc.org/

  • International Conference on Harmonization (ICH) (1998) ICH Harmonized Guidance E5(R1): ethnic factors in the acceptability of foreign clinical data. ICH web site [online], http://www.ich.org/LOB/media/MEDIA481.pdf

  • Katz DA, Murray B, Bhathena A, Sahelijo L (2008) Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy. Nat Rev Drug Discov 7:293–305

    Article  CAS  PubMed  Google Scholar 

  • Kirchheiner J, Fuhr U, Brockmöller J (2005) Pharmacogenetics-based therapeutic recommendations – ready for clinical practice? Nat Rev Drug Discov 4:639–647

    Article  CAS  PubMed  Google Scholar 

  • Kirk RJ, Hung JL, Horner SR, Perez JT (2008) Implications of pharmacogenomics for drug development. Exp Biol Med 233:1484–1497

    Article  CAS  Google Scholar 

  • Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A (2008) HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579

    Article  PubMed  Google Scholar 

  • McCarthy A, Kerr M, Abadie E (2004) Report on the joint EFPIA, DIA and EMEA pharmacogenetics workshop: moving toward clinical application. Pharmacogenomics 5:731–739

    Article  CAS  PubMed  Google Scholar 

  • McLeod HL, Siva C (2002) The thiopurine-S-methyltransferase locus – implications for clinical pharmacogenomics. Pharmacogenomics 3:89–98

    Article  CAS  PubMed  Google Scholar 

  • National Research Council (2007) Committee on applications of toxicogenomic technologies to predictive toxicology and risk assessment, applications of toxicogenomic technologies to predictive toxicology and risk assessment. ISBN: 0-309-11299-0, http://www.nap.edu/catalog/12037.html

  • Nicholls H (2008) 50 cancers to be sequenced. Nat Biotechnol 26:722

    Article  CAS  PubMed  Google Scholar 

  • Olson H, Betton G, Robinson D et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56–67

    Article  CAS  PubMed  Google Scholar 

  • Patnaik M, Renda MJ, Athanasiou MC, Reed CR (2008) The role of pharmacogenetics in treating central nervous system disorders. Exp Biol Med 233:1504–1509

    Article  CAS  Google Scholar 

  • Reis-Filho JS, Westbury C, Pierga JY (2006) The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59:225–231

    Article  CAS  PubMed  Google Scholar 

  • Rink L, Skorobogatko Y, Kossenkov A et al (2009) Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the radiation therapy oncology group phase II clinical trial S-0132. J Clin Oncol 27 (Suppl):S15 Abstract 10533

    Google Scholar 

  • Rosenberger WF, Haines LM (2002) Competing designs for phase I clinical trials: a review. Statist Med 21:2757–2770

    Article  Google Scholar 

  • Roses AD (2008) Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 7:807–817

    Article  CAS  PubMed  Google Scholar 

  • Scott CT, Baker M (2007) Overhauling clinical trials. Nat Biotechnol 25:287–292

    Article  CAS  PubMed  Google Scholar 

  • Suter L, Babiss LE, Wheeldon EB (2004) Toxicogenomics in predictive toxicology in drug development. Chem Biol 11:161–171

    CAS  PubMed  Google Scholar 

  • US Food and Drug Administration (2009) Clinical laboratory improvement amendments (CLIA). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.htm

  • Weiss ST et al (2008) Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 7:568–574

    Article  CAS  PubMed  Google Scholar 

  • Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA (2008) PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 48:849–889

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Officer Molecular Medicine, Novartis Pharma GmbH, Roonstrasse 25, 90429, Nürnberg, Germany

    Klaus Burger

Authors
  1. Klaus Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Burger .

Editor information

Editors and Affiliations

  1. Bohl Str. 28, 73430, Aalen, Germany

    Hans Gerhard Vogel

  2. Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, Building G877, R&D Metabolism and PK Germany, 65926, Frankfurt am Main, Germany

    Jochen Maas

  3. Merz Pharmaceuticals GmbH, Eckenheimer Landstraβe 100, 60318, Frankfurt am Main, Germany

    Alexander Gebauer

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Burger, K. (2011). Pharmacogenomic-Guided Drug Development. In: Vogel, H.G., Maas, J., Gebauer, A. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89891-7_39

Download citation

Publish with us

Policies and ethics

Search

Navigation